Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 6/20 | 0.44 |
| ▸ | PAM | P19021 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165853 | 0.89 | TSHR (0.50) | ALDH1A1MAPK1L3MBTL1NPC1MAPT | |
| SCHEMBL23684580 | 0.82 | PAM (0.65) | ALDH1A1MAPK1L3MBTL1NPC1MAPT | |
| SCHEMBL419807 | 0.81 | ALDH1A1 (0.66) | ALDH1A1MAPK1L3MBTL1PAMTSHR | |
| SCHEMBL52219 | 0.80 | ALDH1A1 (0.52) | ALDH1A1MAPK1L3MBTL1NPC1MAPT | |
| SCHEMBL28008248 | 0.79 | TSHR (0.64) | ALDH1A1MAPK1L3MBTL1NPC1MAPT | |
| SCHEMBL5449272 | 0.78 | MAPK1 (0.46) | ALDH1A1MAPK1L3MBTL1NPC1MAPT | |
| SCHEMBL802817 | 0.78 | ALDH1A1 (0.49) | ALDH1A1MAPK1L3MBTL1NPC1MAPT | |
| SCHEMBL16672447 | 0.78 | LMNA (0.50) | ALDH1A1MAPK1L3MBTL1NPC1MAPT | |
| SCHEMBL19598480 | 0.77 | PPARG (0.48) | ALDH1A1 | |
| SCHEMBL1171919 | 0.76 | TSHR (0.52) | ALDH1A1MAPK1L3MBTL1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1717238-A1 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191395-A1 | Heterocyclic compounds having antifungal activity | ERG28, MANBA, MAN2B1 | ALDH1A1 1357/4885MAPK1 151/4885L3MBTL1 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.